- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02254018
Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck
An Open Phase I Single Dose Escalation Study of Bivatuzumab Mertansine Administered Intravenously in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck With Repeated Administration in Patients With Clinical Benefit
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- male and female patients aged 18 years or older
- patients with histologically confirmed squamous cell carcinoma of the head and neck
- patients with local and / or regional recurrent disease or distant metastases who are refractory to or not amenable to established treatments
- measurable tumour deposits by one or more radiological techniques (MRI, CT)
- life expectancy of at least 6 months
- Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2
- patients must have given written informed consent (which must be consistent with International Conference of Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation)
Exclusion Criteria:
- hypersensitivity to humanised or murine antibodies, immunoconjugates or the excipients of the trial drugs
- known secondary malignancy requiring therapy
- active infectious disease
- brain metastases
- neuropathy grade 2 or above (excluding pre-existing neuropathy of cranial nerves due to surgery, radiotherapy or tumour growth)
- absolute neutrophil count less than 1,500/mm3
- platelet count less than 100,000/mm3
- bilirubin greater than 1.5 mg/dl (> 26 μmol/L, système internationale (SI) unit equivalent)
- aspartate amino transferase (AST) and/or alanine amino transferase (ALT) greater than 3 times the upper limit of normal
- serum creatinine greater than 1.5 mg/dl (> 132 μmol/L, SI unit equivalent)
- concomitant non-oncological diseases which are considered relevant for the evaluation of the safety of the trial drug
- chemo- or immunotherapy within the past three weeks prior to treatment with the trial drug or during the trial
- radiotherapy to head and neck region within the past four weeks before inclusion or during the trial
- men and women who are sexually active and unwilling to use a medically acceptable method of contraception
- pregnancy or lactation
- treatment with other investigational drugs or participation in another clinical trial within the past three weeks before start of therapy or concomitantly with this trial
- patients unable to comply with the protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: bivatuzumab mertansine
single dose escalation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum tolerated dose (MTD) of bivatuzumab mertansine
Time Frame: up to day 21
|
up to day 21
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concentration of bivatuzumab mertansine
Time Frame: up to day 21
|
up to day 21
|
|
Concentration of CD44v6 recognising IgG antibodies (anti-CD44v6-IgG)
Time Frame: up to day 21
|
up to day 21
|
|
Number of patients with development of human anti-human antibodies (HAHA)
Time Frame: up to day 21
|
up to day 21
|
|
Number of patients with adverse events
Time Frame: up to day 21
|
grading according to the common toxicity criteria (CTC)
|
up to day 21
|
Number of patients with clinically significant changes in laboratory parameters
Time Frame: up to day 21
|
up to day 21
|
|
Number of patients with clinically significant changes in vital signs
Time Frame: up to day 21
|
up to day 21
|
|
Tumor response
Time Frame: up to 1 year
|
according to the response evaluation criteria in solid tumours (RECIST)
|
up to 1 year
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Neoplasms, Squamous Cell
- Head and Neck Neoplasms
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Immunoconjugates
- Immunotoxins
- Maytansine
- Bivatuzumab mertansine
Other Study ID Numbers
- 1191.2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).
For more details refer to: https://www.mystudywindow.com/msw/datatransparency
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Neoplasms
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
IntraGel TherapeuticsNot yet recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHead and Neck CarcinomaUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisActive, not recruiting
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Completed
-
Jonsson Comprehensive Cancer CenterWithdrawnHead and Neck CarcinomaUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnHead and Neck CarcinomaUnited States
Clinical Trials on bivatuzumab mertansine
-
Boehringer IngelheimTerminated
-
Boehringer IngelheimTerminated
-
Boehringer IngelheimCompleted
-
M.D. Anderson Cancer CenterImmunoGen, Inc.Completed
-
ImmunoGen, Inc.CompletedOvarian Cancer | SCLC | Merkel Cell CarcinomaUnited States, United Kingdom
-
ImmunoGen, Inc.CompletedMultiple MyelomaUnited States, Argentina
-
ImmunoGen, Inc.TerminatedSmall Cell Lung CancerUnited States, Spain, Canada, United Kingdom
-
ImmunoGen, Inc.CompletedSmall Cell Lung CancerUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Recurrent Rhabdomyosarcoma | Wilms Tumor | Recurrent Malignant Peripheral Nerve Sheath Tumor | Recurrent Synovial Sarcoma | Pleuropulmonary BlastomaUnited States
-
ImmunoGen, Inc.Completed